Year-End Recognition
As 2025 drew to a close, Medgen received welcome news. According to the newly released "Shenzhen Key New Materials First-Batch Application Demonstration Directory (2025 Edition)" published by the Shenzhen Municipal Bureau of Industry and Information Technology, Medgen Life Science's independently developed "bone graft material" was successfully selected for inclusion.
The directory is organized and certified by the Shenzhen Bureau of Industry and Information Technology to encourage and support the R&D and application promotion of new materials, driving high-quality development of Shenzhen's new materials industry. Selected products must meet strict criteria including "first market launch, technologically advanced, reliable quality, and demonstrating significant socioeconomic benefits."
Medgen's bone graft material selection confirms official recognition of its technological leadership, clinical value, and market potential.
Product Features
Medgen's bone graft material is the company's core innovative biomedical material product, primarily used for bone defect repair and regeneration in orthopedics, oral surgery, and sports medicine. The material offers the following key advantages:
Excellent osteoconductive performance: A unique biomimetic porous structure provides an ideal "scaffold" for neovascularization and osteocyte growth, effectively guiding directional regeneration and functional reconstruction of autologous bone tissue.
Outstanding biocompatibility: Pure material composition with a degradation rate matched to new bone growth, avoiding secondary surgery and ensuring high safety.
Versatile adaptability: Can be manufactured in various forms to match clinical needs, accommodating bone defect repair at different sites and sizes with convenient clinical handling.
Approved Products
Using this material, Medgen has developed two products — pre-filled injectable artificial bone (BoneSwift™) and oral bone graft material (PoroGraft®) — both of which have obtained NMPA Class III medical device registration certificates in China.
Notably, the injectable artificial bone was the first to obtain a Class D (high-risk) medical device registration certificate in Vietnam, marking the company's first step toward international expansion. Additional innovative products are in active development.
Outlook
The successful inclusion of Medgen's bone graft material not only enhances the product's market competitiveness and brand influence, but also creates favorable conditions for further clinical promotion and market access.
Medgen will continue to uphold its innovation-driven development philosophy, advancing more high-performance biomedical materials to market and contributing to the Healthy China initiative.